Category: GLP-1/GIP/Glucagon Triple Agonist Research Peptide

Reta 10mg is a high-purity research vial of Retatrutide, a first-in-class triple agonist targeting the GLP-1, GIP, and Glucagon receptors. This powerful multi-pathway mechanism has made Retatrutide one of the most promising investigational compounds in the fields of weight management, type 2 diabetes, and metabolic health.

By simultaneously activating three metabolic hormone receptors, Reta 10mg supports research into enhanced glucose control, appetite suppression, fat reduction, and improved energy expenditure. Clinical studies have highlighted its potential as a next-generation treatment surpassing single or dual agonist approaches.

Key Features:

• 10mg high-potency research vial

• First-in-class triple receptor agonist (GLP-1, GIP, Glucagon)

• Research focus: obesity, insulin resistance, fatty liver, and metabolic disorders

• Longer half-life for convenient weekly dosing in research settings

• Synergistic effects on satiety, glycaemic regulation, and weight reduction

CAS Number: 2381089-83-2

Disclaimer:
Reta 10mg is provided for research use only. It is not a medicine and is not intended for human consumption.